Review
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 55-74
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.55
Table 1 Association with Helicobacter pylori infection and oral squamous cell carcinoma

Prevalence of H. pylori
Diagnostic tool of H. pylori
Study design
P value
Fernando et al[13]Betel Chewers (20/104; 19.2%) and non-betel chewers (4/69; 5.8%)SerologyCase- control study< 0.05
Grandis et al[14]Case 57% vs controls 62%SerologyCase- control study> 0.05
Dayama et al [15]OR: 3.0; 95%CI: 0.34-26.4Serum and tissue samples (PCR and culture)Case- control studyNA
Gupta et al[16]OR: 2.29; 95%CI: 0.61-8.68Serology, PCR, cultureMeta-analysisNA
Meng et al[17]Case 35.3% vs controls 54.8%Serology, PCR, histochemical stainingCase- control study0.012
Table 2 Helicobacter pylori infection effect in whole gastroenterology tract malignant diseases
Site
Malignant cell type
H. pylori effect
Odds ratio
95%CI
P value
Gastrointestinal transit time
Oral cavitySquamous cell carcinomaNon related1 min
Pharynx-larynxSquamous cell carcinomaIncreased risk12.871.71-4.84< 0.051 s
OesophagusSquamous cell carcinomaNon related4-8 s
AdenocarcinomaProtected effect0.560.46-0.68< 0.05
StomachAdenocarcinomaCause-effect5.93.4-10.3< 0.052-4 h
MALT lymphomaCause-effect1.961.0-3.9< 0.05
Small intestineLymphomaNon related6 h
ColorectumAdenocarcinomaPartial cause-effect1.71.64-1.76< 0.0510 h to days
LymphomaNon related
Table 3 Association with Helicobacter pylori infection and pharyngeal-laryngeal cancer

Prevalence of H. pylori
Diagnostic tool of H. pylori
Study design
P value
Zhou et al[30]Laryngeal CA: OR: 3.28; 95%CI: 1.91-5.63Histochemical, PCR, rapid urease testMeta-analysis< 0.0001
Pharyngeal CA: OR: 1.35; 95%CI: 0.86-2.12= 0.188
Siupsinskiene et al[31]Laryngeal CA: Case 46.2% and controls 9.1%Rapid urease testCase- control study< 0.05
Zhou et al[32]Laryngeal CA: OR: 2.3 95%CI: 1.28-3.23Serology, histopathological methodsMeta-analysis< 0.01
Pirzadeh et al[34]Laryngeal CA: Case 49.2% and controls 40%Rapid urease testCase- control studyNA
Table 4 Association with Helicobacter pylori infection and Esophageal cancer

Prevalence of H. pylori
Diagnostic tool of H. pylori
Study design
P value
Rokkas et al[44]EAC: 0.52 (95%CI: 0.37-0.73)Serology and/or histologyMeta-analysisEAC: P < 0.001
ESCC: 0.85 (95%CI: 0.55-1.33)ESCC: P = 0.48
Islami et al[45]EAC: 0.56 (95%CI: 0.46-0.68)Serology and/or histologyMeta-analysisNA
ESCC: 1.10 (95%CI: 0.78-1.55)
Nie et al[46]EAC: 0.57 (95%CI: 0.44-0.73)Serology and/or histology; rapid urease testMeta-analysisNA
ESCC:1.16 (95%CI: 0.8.-1.60)
Xie et al[47]EAC: 0.59 (95%CI: 0.51-0.68)Serology and/or histology; rapid urease testMeta-analysisNA
ESCC: 0.97 (95%CI: 0.76-1.24)
ESCC in Eastern: 0.66 (95%CI: 0.43-0.89)
Table 5 Association with Helicobacter pylori infection and gastric cancer

Prevalence of H. pylori
Diagnostic tool of H. pylori
Study design
P value
Helicobacter and Cancer Collaborative Group[68]Non-cardia GC: OR: 5.9; 95%CI: 3.4-10.3Serology and/or histologyMeta-analysisP = 0.002
Huang et al[66]For cagA-positive OR: 1.64; 95%CI: 1.21-2.241Serology and/or histologyMeta-analysisNA
Gastric cancer incidence decreased after H. pylori eradication
Lee et al[70]Incidence rate ratio = 0.53; 95%CI: 0.44-0.64Serology and/or histology; rapid urease testMeta-analysisNA
Chiang et al[71]Reducing GC incidence of 0.53; 95%CI :0.3-0.69Rapid urease testProspective studyP < 0.001
Table 6 Association with Helicobacter pylori infection and gastrointestinal tract lymphoma

Prevalence of H. pylori
Diagnostic tool for H. pylori
Study design
P value
Parsonnet et al[95] (Gastric NHL)OR: 6.3; 95%CI: 2.0-19.9SerologyCase- control studyNA
Ishikura et al[97] (Gastric lymphoma overall)OR: 2.14; 95%CI: 1.3-3.5SerologyCase- control studyP = 0.003
Ishikura et al[97] (Gastric MALT)OR: 1.96; 95%CI: 1.0-3.9SerologyCase- control studyP = 0.051
Ishikura et al[97] (Gastric DLBCL)OR: 1.92; 95%CI: 0.74-4.95SerologyCase- control studyP = 0.178
Parsonnet et al[95] (Non-gastric NHL)OR: 1.2; 95%CI: 0.5-3.0SerologyCase- control studyNA
Table 7 Association with Helicobacter pylori infection and colorectal adenoma/ cancer

Prevalence of H. pylori
Diagnostic tool of H. pylori
Study design
P value
Hu et al[113]OR: 1.44; 95%CI: 1.2-1.73Rapid urease testRetrospectiveP < 0.001
Sonnenberg et al[122]OR: 1.52; 95%CI: 1.46-1.57HistologyRetrospectiveNA
Liou et al[124]Case 14.2% vs controls 11.8%13C-UBTCase-control studyP = 0.513
Choi et al[126]OR: 1.49; 95%CI: 1.37-1.62Serology, histology, rapid urease test and 13C-UBTMeta-analysisP < 0.001
Zuo et al[127]1OR: 1.70; 95%CI: 1.64-1.76Serology, histology and rapid urease testMeta-analysisNA
Colorectal adenoma incidence decreased after H. pylori eradication
Hu et al[133]2HR: 3.04; 95%CI: 1.754-5.280Rapid urease testRetrospective cohortP < 0.001